한글목차

개요

신장 이식 치료제 시장은 2023년부터 2028년까지 6억 4,315만 달러, 예측 기간 동안 4.49%의 CAGR로 성장할 것으로 예상됩니다.

본 보고서는 신장 이식 치료제 시장에 대한 전반적인 분석, 시장 규모와 예측, 동향, 성장 촉진요인, 과제, 약 25개 벤더를 포함한 벤더 분석 등을 정리하여 전해드립니다.

현재 시장 시나리오, 최신 동향 및 촉진요인, 전체 시장 환경에 대한 최신 분석을 제공하며, CKD 및 신장 질환의 유병률 증가, 여러 제형의 약물 가용성, 신장 이식에서 면역억제제에 대한 높은 의존도 등이 시장을 주도하고 있습니다.

이 보고서는 향후 몇 년 동안 신장 이식 치료제 시장의 성장을 주도할 주요 요인 중 하나로 신장 이식을 위한 새로운 기술을 꼽았습니다. 또한, 신장이식 관련 보험급여 정책 및 전략적 제휴의 증가도 이 시장에 큰 수요를 창출할 것으로 예상됩니다.

목차

제1장 주요 요약

• 시장 개요

제2장 시장 상황

• 시장 생태계

제3장 시장 규모

• 시장 정의
• 시장 부문 분석
• 시장 규모 2023
• 시장 전망 2023-2028

제4장 시장 규모 실적

• 신장 이식 치료제 세계 시장 2018-2022
• 제품별 부문 분석 2018-2022
• 유통 채널별 부문 분석 2018-2022
• 지역별 부문 분석 2018-2022
• 국가별 부문 분석 2018-2022

제5장 Five Forces 분석

• Five Forces 요약
• 구매자의 교섭력
• 공급 기업의 교섭력
• 신규 참여업체의 위협
• 대체품의 위협
• 경쟁의 위협
• 시장 상황

제6장 시장 세분화 : 제품별

• 시장 부문
• 비교 : 제품별
• 선택적 사이토카인 억제제 : 시장 규모와 예측 2023-2028
• 면역 억제성 대사 대항 물질 : 시장 규모와 예측 2023-2028
• 기타 약제 : 시장 규모와 예측 2023-2028
• 시장 기회 : 제품별

제7장 시장 세분화 : 유통 채널별

• 시장 부문
• 비교 : 유통 채널별
• 병원 약국 : 시장 규모와 예측 2023-2028
• 소매 약국 : 시장 규모와 예측 2023-2028
• 온라인 약국 : 시장 규모와 예측 2023-2028
• 시장 기회 : 유통 채널별

제8장 고객 상황

• 고객 상황 개요

제9장 지역별 상황

• 지역별 세분화
• 지역별 비교
• 북미 : 시장 규모와 예측 2023-2028
• 유럽 : 시장 규모와 예측 2023-2028
• 아시아 : 시장 규모와 예측 2023-2028
• 세계 기타 지역 : 시장 규모와 예측 2023-2028
• 미국 : 시장 규모와 예측 2023-2028
• 중국 : 시장 규모와 예측 2023-2028
• 캐나다 : 시장 규모와 예측 2023-2028
• 독일 : 시장 규모와 예측 2023-2028
• 영국 : 시장 규모와 예측 2023-2028
• 시장 기회 : 지역 상황별

제10장 촉진요인, 과제 및 동향

• 시장 성장 촉진요인
• 시장 과제
• 성장 촉진요인과 과제의 영향
• 시장 동향

제11장 벤더 상황

• 개요
• 벤더 상황
• 혼란 상황
• 업계 리스크

제12장 벤더 분석

• 대상 벤더
• 벤더의 시장 포지셔닝
• AbbVie Inc.
• Asahi Kasei Corp.
• Astellas Pharma Inc.
• Bristol Myers Squibb Co.
• Dr Reddys Laboratories Ltd.
• F. Hoffmann La Roche Ltd.
• GlaxoSmithKline Plc
• Hansa Biopharma AB
• Novartis AG
• Organ Recovery Systems Inc.
• Pfizer Inc.
• Sanofi SA
• Strides Pharma Science Ltd.
• TFF Pharmaceuticals Inc.
• TolerogenixX GmbH

제13장 부록

영문목차

Abstract

The kidney transplantation therapeutics market is forecasted to grow by USD 643.15 mn during 2023-2028, accelerating at a CAGR of 4.49% during the forecast period. The report on the kidney transplantation therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising prevalence of CKD and renal impairments, availability of drugs in multiple dosage forms, and high dependency on immunosuppressants for kidney transplantation.

Technavio's kidney transplantation therapeutics market is segmented as below:

By Product

• Selective cytokine inhibitors
• Immunosuppressive antimetabolites
• Other drug

By Distribution Channel

• Hospital pharmacy
• Retail pharmacy
• Online pharmacy

By Geographical Landscape

• North America
• Europe
• Asia
• Rest of World (ROW)

This study identifies the novel techniques for kidney transplantation as one of the prime reasons driving the kidney transplantation therapeutics market growth during the next few years. Also, reimbursement policies for kidney transplantation and increasing strategic alliances will lead to sizable demand in the market.

The report on the kidney transplantation therapeutics market covers the following areas:

• Kidney transplantation therapeutics market sizing
• Kidney transplantation therapeutics market forecast
• Kidney transplantation therapeutics market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading kidney transplantation therapeutics market vendors that include AbbVie Inc., Asahi Kasei Corp., Astellas Pharma Inc., B.Braun SE, Bristol Myers Squibb Co., Dr Reddys Laboratories Ltd., F. Hoffmann La Roche Ltd., Fresenius Medical Care AG and Co. KGaA, GlaxoSmithKline Plc, Hansa Biopharma AB, Novartis AG, Organ Recovery Systems Inc., Pfizer Inc., Sanofi SA, Strides Pharma Science Ltd., TFF Pharmaceuticals Inc., TolerogenixX GmbH, TransMedics Inc., and Transonic Systems Inc.. Also, the kidney transplantation therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
• Exhibit 01: Executive Summary - Chart on Market Overview
• Exhibit 02: Executive Summary - Data Table on Market Overview
• Exhibit 03: Executive Summary - Chart on Global Market Characteristics
• Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
• Exhibit 05: Executive Summary - Chart on Market Segmentation by Product
• Exhibit 06: Executive Summary - Chart on Market Segmentation by Distribution Channel
• Exhibit 07: Executive Summary - Chart on Incremental Growth
• Exhibit 08: Executive Summary - Data Table on Incremental Growth
• Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem
• Exhibit 10: Parent market
• Exhibit 11: Market Characteristics

3 Market Sizing

• 3.1 Market definition
• Exhibit 12: Offerings of vendors included in the market definition
• 3.2 Market segment analysis
• Exhibit 13: Market segments
• 3.3 Market size 2023
• 3.4 Market outlook: Forecast for 2023-2028
• Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ million)
• Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
• Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
• Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

4 Historic Market Size

• 4.1 Global kidney transplantation therapeutics market 2018 - 2022
• Exhibit 18: Historic Market Size - Data Table on global kidney transplantation therapeutics market 2018 - 2022 ($ million)
• 4.2 Product Segment Analysis 2018 - 2022
• Exhibit 19: Historic Market Size - Product Segment 2018 - 2022 ($ million)
• 4.3 Distribution Channel Segment Analysis 2018 - 2022
• Exhibit 20: Historic Market Size - Distribution Channel Segment 2018 - 2022 ($ million)
• 4.4 Geography Segment Analysis 2018 - 2022
• Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ million)
• 4.5 Country Segment Analysis 2018 - 2022
• Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ million)

5 Five Forces Analysis

• 5.1 Five forces summary
• Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
• 5.2 Bargaining power of buyers
• Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
• 5.3 Bargaining power of suppliers
• Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
• 5.4 Threat of new entrants
• Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028
• 5.5 Threat of substitutes
• Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028
• 5.6 Threat of rivalry
• Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028
• 5.7 Market condition
• Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

6 Market Segmentation by Product

• 6.1 Market segments
• Exhibit 30: Chart on Product - Market share 2023-2028 (%)
• Exhibit 31: Data Table on Product - Market share 2023-2028 (%)
• 6.2 Comparison by Product
• Exhibit 32: Chart on Comparison by Product
• Exhibit 33: Data Table on Comparison by Product
• 6.3 Selective cytokine inhibitors - Market size and forecast 2023-2028
• Exhibit 34: Chart on Selective cytokine inhibitors - Market size and forecast 2023-2028 ($ million)
• Exhibit 35: Data Table on Selective cytokine inhibitors - Market size and forecast 2023-2028 ($ million)
• Exhibit 36: Chart on Selective cytokine inhibitors - Year-over-year growth 2023-2028 (%)
• Exhibit 37: Data Table on Selective cytokine inhibitors - Year-over-year growth 2023-2028 (%)
• 6.4 Immunosuppressive antimetabolites - Market size and forecast 2023-2028
• Exhibit 38: Chart on Immunosuppressive antimetabolites - Market size and forecast 2023-2028 ($ million)
• Exhibit 39: Data Table on Immunosuppressive antimetabolites - Market size and forecast 2023-2028 ($ million)
• Exhibit 40: Chart on Immunosuppressive antimetabolites - Year-over-year growth 2023-2028 (%)
• Exhibit 41: Data Table on Immunosuppressive antimetabolites - Year-over-year growth 2023-2028 (%)
• 6.5 Other drug - Market size and forecast 2023-2028
• Exhibit 42: Chart on Other drug - Market size and forecast 2023-2028 ($ million)
• Exhibit 43: Data Table on Other drug - Market size and forecast 2023-2028 ($ million)
• Exhibit 44: Chart on Other drug - Year-over-year growth 2023-2028 (%)
• Exhibit 45: Data Table on Other drug - Year-over-year growth 2023-2028 (%)
• 6.6 Market opportunity by Product
• Exhibit 46: Market opportunity by Product ($ million)
• Exhibit 47: Data Table on Market opportunity by Product ($ million)

7 Market Segmentation by Distribution Channel

• 7.1 Market segments
• Exhibit 48: Chart on Distribution Channel - Market share 2023-2028 (%)
• Exhibit 49: Data Table on Distribution Channel - Market share 2023-2028 (%)
• 7.2 Comparison by Distribution Channel
• Exhibit 50: Chart on Comparison by Distribution Channel
• Exhibit 51: Data Table on Comparison by Distribution Channel
• 7.3 Hospital pharmacy - Market size and forecast 2023-2028
• Exhibit 52: Chart on Hospital pharmacy - Market size and forecast 2023-2028 ($ million)
• Exhibit 53: Data Table on Hospital pharmacy - Market size and forecast 2023-2028 ($ million)
• Exhibit 54: Chart on Hospital pharmacy - Year-over-year growth 2023-2028 (%)
• Exhibit 55: Data Table on Hospital pharmacy - Year-over-year growth 2023-2028 (%)
• 7.4 Retail pharmacy - Market size and forecast 2023-2028
• Exhibit 56: Chart on Retail pharmacy - Market size and forecast 2023-2028 ($ million)
• Exhibit 57: Data Table on Retail pharmacy - Market size and forecast 2023-2028 ($ million)
• Exhibit 58: Chart on Retail pharmacy - Year-over-year growth 2023-2028 (%)
• Exhibit 59: Data Table on Retail pharmacy - Year-over-year growth 2023-2028 (%)
• 7.5 Online pharmacy - Market size and forecast 2023-2028
• Exhibit 60: Chart on Online pharmacy - Market size and forecast 2023-2028 ($ million)
• Exhibit 61: Data Table on Online pharmacy - Market size and forecast 2023-2028 ($ million)
• Exhibit 62: Chart on Online pharmacy - Year-over-year growth 2023-2028 (%)
• Exhibit 63: Data Table on Online pharmacy - Year-over-year growth 2023-2028 (%)
• 7.6 Market opportunity by Distribution Channel
• Exhibit 64: Market opportunity by Distribution Channel ($ million)
• Exhibit 65: Data Table on Market opportunity by Distribution Channel ($ million)

8 Customer Landscape

• 8.1 Customer landscape overview
• Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

• 9.1 Geographic segmentation
• Exhibit 67: Chart on Market share By Geographical Landscape 2023-2028 (%)
• Exhibit 68: Data Table on Market share By Geographical Landscape 2023-2028 (%)
• 9.2 Geographic comparison
• Exhibit 69: Chart on Geographic comparison
• Exhibit 70: Data Table on Geographic comparison
• 9.3 North America - Market size and forecast 2023-2028
• Exhibit 71: Chart on North America - Market size and forecast 2023-2028 ($ million)
• Exhibit 72: Data Table on North America - Market size and forecast 2023-2028 ($ million)
• Exhibit 73: Chart on North America - Year-over-year growth 2023-2028 (%)
• Exhibit 74: Data Table on North America - Year-over-year growth 2023-2028 (%)
• 9.4 Europe - Market size and forecast 2023-2028
• Exhibit 75: Chart on Europe - Market size and forecast 2023-2028 ($ million)
• Exhibit 76: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
• Exhibit 77: Chart on Europe - Year-over-year growth 2023-2028 (%)
• Exhibit 78: Data Table on Europe - Year-over-year growth 2023-2028 (%)
• 9.5 Asia - Market size and forecast 2023-2028
• Exhibit 79: Chart on Asia - Market size and forecast 2023-2028 ($ million)
• Exhibit 80: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
• Exhibit 81: Chart on Asia - Year-over-year growth 2023-2028 (%)
• Exhibit 82: Data Table on Asia - Year-over-year growth 2023-2028 (%)
• 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
• Exhibit 83: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
• Exhibit 84: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
• Exhibit 85: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
• Exhibit 86: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
• 9.7 US - Market size and forecast 2023-2028
• Exhibit 87: Chart on US - Market size and forecast 2023-2028 ($ million)
• Exhibit 88: Data Table on US - Market size and forecast 2023-2028 ($ million)
• Exhibit 89: Chart on US - Year-over-year growth 2023-2028 (%)
• Exhibit 90: Data Table on US - Year-over-year growth 2023-2028 (%)
• 9.8 China - Market size and forecast 2023-2028
• Exhibit 91: Chart on China - Market size and forecast 2023-2028 ($ million)
• Exhibit 92: Data Table on China - Market size and forecast 2023-2028 ($ million)
• Exhibit 93: Chart on China - Year-over-year growth 2023-2028 (%)
• Exhibit 94: Data Table on China - Year-over-year growth 2023-2028 (%)
• 9.9 Canada - Market size and forecast 2023-2028
• Exhibit 95: Chart on Canada - Market size and forecast 2023-2028 ($ million)
• Exhibit 96: Data Table on Canada - Market size and forecast 2023-2028 ($ million)
• Exhibit 97: Chart on Canada - Year-over-year growth 2023-2028 (%)
• Exhibit 98: Data Table on Canada - Year-over-year growth 2023-2028 (%)
• 9.10 Germany - Market size and forecast 2023-2028
• Exhibit 99: Chart on Germany - Market size and forecast 2023-2028 ($ million)
• Exhibit 100: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
• Exhibit 101: Chart on Germany - Year-over-year growth 2023-2028 (%)
• Exhibit 102: Data Table on Germany - Year-over-year growth 2023-2028 (%)
• 9.11 UK - Market size and forecast 2023-2028
• Exhibit 103: Chart on UK - Market size and forecast 2023-2028 ($ million)
• Exhibit 104: Data Table on UK - Market size and forecast 2023-2028 ($ million)
• Exhibit 105: Chart on UK - Year-over-year growth 2023-2028 (%)
• Exhibit 106: Data Table on UK - Year-over-year growth 2023-2028 (%)
• 9.12 Market opportunity By Geographical Landscape
• Exhibit 107: Market opportunity By Geographical Landscape ($ million)
• Exhibit 108: Data Tables on Market opportunity By Geographical Landscape ($ million)

10 Drivers, Challenges, and Trends

• 10.1 Market drivers
• 10.2 Market challenges
• 10.3 Impact of drivers and challenges
• Exhibit 109: Impact of drivers and challenges in 2023 and 2028
• 10.4 Market trends

11 Vendor Landscape

• 11.1 Overview
• 11.2 Vendor landscape
• Exhibit 110: Overview on Criticality of inputs and Factors of differentiation
• 11.3 Landscape disruption
• Exhibit 111: Overview on factors of disruption
• 11.4 Industry risks
• Exhibit 112: Impact of key risks on business

12 Vendor Analysis

• 12.1 Vendors covered
• Exhibit 113: Vendors covered
• 12.2 Market positioning of vendors
• Exhibit 114: Matrix on vendor position and classification
• 12.3 AbbVie Inc.
• Exhibit 115: AbbVie Inc. - Overview
• Exhibit 116: AbbVie Inc. - Product / Service
• Exhibit 117: AbbVie Inc. - Key news
• Exhibit 118: AbbVie Inc. - Key offerings
• 12.4 Asahi Kasei Corp.
• Exhibit 119: Asahi Kasei Corp. - Overview
• Exhibit 120: Asahi Kasei Corp. - Business segments
• Exhibit 121: Asahi Kasei Corp. - Key news
• Exhibit 122: Asahi Kasei Corp. - Key offerings
• Exhibit 123: Asahi Kasei Corp. - Segment focus
• 12.5 Astellas Pharma Inc.
• Exhibit 124: Astellas Pharma Inc. - Overview
• Exhibit 125: Astellas Pharma Inc. - Product / Service
• Exhibit 126: Astellas Pharma Inc. - Key news
• Exhibit 127: Astellas Pharma Inc. - Key offerings
• 12.6 Bristol Myers Squibb Co.
• Exhibit 128: Bristol Myers Squibb Co. - Overview
• Exhibit 129: Bristol Myers Squibb Co. - Product / Service
• Exhibit 130: Bristol Myers Squibb Co. - Key news
• Exhibit 131: Bristol Myers Squibb Co. - Key offerings
• 12.7 Dr Reddys Laboratories Ltd.
• Exhibit 132: Dr Reddys Laboratories Ltd. - Overview
• Exhibit 133: Dr Reddys Laboratories Ltd. - Business segments
• Exhibit 134: Dr Reddys Laboratories Ltd. - Key offerings
• Exhibit 135: Dr Reddys Laboratories Ltd. - Segment focus
• 12.8 F. Hoffmann La Roche Ltd.
• Exhibit 136: F. Hoffmann La Roche Ltd. - Overview
• Exhibit 137: F. Hoffmann La Roche Ltd. - Business segments
• Exhibit 138: F. Hoffmann La Roche Ltd. - Key news
• Exhibit 139: F. Hoffmann La Roche Ltd. - Key offerings
• Exhibit 140: F. Hoffmann La Roche Ltd. - Segment focus
• 12.9 GlaxoSmithKline Plc
• Exhibit 141: GlaxoSmithKline Plc - Overview
• Exhibit 142: GlaxoSmithKline Plc - Business segments
• Exhibit 143: GlaxoSmithKline Plc - Key news
• Exhibit 144: GlaxoSmithKline Plc - Key offerings
• Exhibit 145: GlaxoSmithKline Plc - Segment focus
• 12.10 Hansa Biopharma AB
• Exhibit 146: Hansa Biopharma AB - Overview
• Exhibit 147: Hansa Biopharma AB - Product / Service
• Exhibit 148: Hansa Biopharma AB - Key offerings
• 12.11 Novartis AG
• Exhibit 149: Novartis AG - Overview
• Exhibit 150: Novartis AG - Business segments
• Exhibit 151: Novartis AG - Key offerings
• Exhibit 152: Novartis AG - Segment focus
• 12.12 Organ Recovery Systems Inc.
• Exhibit 153: Organ Recovery Systems Inc. - Overview
• Exhibit 154: Organ Recovery Systems Inc. - Product / Service
• Exhibit 155: Organ Recovery Systems Inc. - Key offerings
• 12.13 Pfizer Inc.
• Exhibit 156: Pfizer Inc. - Overview
• Exhibit 157: Pfizer Inc. - Product / Service
• Exhibit 158: Pfizer Inc. - Key news
• Exhibit 159: Pfizer Inc. - Key offerings
• 12.14 Sanofi SA
• Exhibit 160: Sanofi SA - Overview
• Exhibit 161: Sanofi SA - Business segments
• Exhibit 162: Sanofi SA - Key news
• Exhibit 163: Sanofi SA - Key offerings
• Exhibit 164: Sanofi SA - Segment focus
• 12.15 Strides Pharma Science Ltd.
• Exhibit 165: Strides Pharma Science Ltd. - Overview
• Exhibit 166: Strides Pharma Science Ltd. - Business segments
• Exhibit 167: Strides Pharma Science Ltd. - Key offerings
• Exhibit 168: Strides Pharma Science Ltd. - Segment focus
• 12.16 TFF Pharmaceuticals Inc.
• Exhibit 169: TFF Pharmaceuticals Inc. - Overview
• Exhibit 170: TFF Pharmaceuticals Inc. - Product / Service
• Exhibit 171: TFF Pharmaceuticals Inc. - Key offerings
• 12.17 TolerogenixX GmbH
• Exhibit 172: TolerogenixX GmbH - Overview
• Exhibit 173: TolerogenixX GmbH - Product / Service
• Exhibit 174: TolerogenixX GmbH - Key offerings

13 Appendix

• 13.1 Scope of the report
• 13.2 Inclusions and exclusions checklist
• Exhibit 175: Inclusions checklist
• Exhibit 176: Exclusions checklist
• 13.3 Currency conversion rates for US$
• Exhibit 177: Currency conversion rates for US$
• 13.4 Research methodology
• Exhibit 178: Research methodology
• Exhibit 179: Validation techniques employed for market sizing
• Exhibit 180: Information sources
• 13.5 List of abbreviations
• Exhibit 181: List of abbreviations